Conference Correspondent

Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

Final Analysis from RESONATE: Six-Year Follow-Up in Patients with Previously Treated CLL/SLL Receiving Ibrutinib
Read More
Effect of Dose Modifications on Response to Duvelisib in Patients with Relapsed/Refractory CLL/SLL in the DUO Trial
Read More
Cost-Effectiveness Comparison of Ibrutinib, Chemotherapy, and Chemoimmunotherapy in First-Line Treatment of CLL
Read More
ECOG-ACRIN Cancer Research Group: Phase 3 Study of Ibrutinib-Based Therapy in Untreated Younger Patients with CLL
Read More
Prognostic Testing and Treatment Approaches in Patients with CLL: Interim Analysis of the informCLL Real-World Registry
Read More
Acalabrutinib in Patients with Relapsed/Refractory and High-Risk, Treatment-Naïve CLL
Read More
Frontline Ibrutinib Treatment Is Associated with Lower Total Cost of Care Compared with Chemoimmunotherapy in Patients with CLL
Read More
Improved MRD Response Rates with Ibrutinib and Obinutuzumab in Patients with CLL
Read More
MURANO Study Explores Potential for Venetoclax-Rituximab Combination Therapy in Relapsed/Refractory CLL
Read More
Ibrutinib Treatment in Waldenström’s Macroglobulinemia: Follow-Up Efficacy and Safety from the iNNOVATE Study
Read More
Page 6 of 25
Results 51 - 60 of 242
SUBSCRIBE
© Amplity Health. All rights reserved.